Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been given an average rating of “Moderate Buy” by the thirteen research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and twelve have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $46.6667.

Several research analysts have weighed in on the company. Wolfe Research assumed coverage on Avalo Therapeutics in a report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price target for the company. Mizuho boosted their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Piper Sandler reiterated an “overweight” rating and issued a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Citizens Jmp cut their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Finally, Bank of America assumed coverage on Avalo Therapeutics in a report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target for the company.

Avalo Therapeutics Stock Performance

AVTX stock opened at $15.40 on Thursday. Avalo Therapeutics has a 1 year low of $4.47 and a 1 year high of $24.27. The stock’s 50 day moving average price is $15.53 and its 200 day moving average price is $16.12. The firm has a market cap of $809.58 million, a P/E ratio of -2.82 and a beta of 0.83.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. On average, research analysts predict that Avalo Therapeutics will post -2.58 earnings per share for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 8,458 shares of the business’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total value of $110,715.22. Following the completion of the transaction, the chief financial officer directly owned 8,880 shares in the company, valued at approximately $116,239.20. The trade was a 48.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $18.01, for a total value of $71,499.70. Following the completion of the transaction, the insider owned 3,622 shares of the company’s stock, valued at $65,232.22. This trade represents a 52.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 112,586 shares of company stock worth $2,089,651. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AVTX. Caligan Partners LP acquired a new stake in shares of Avalo Therapeutics during the 3rd quarter worth $10,592,000. Balyasny Asset Management L.P. acquired a new stake in shares of Avalo Therapeutics during the 3rd quarter worth $10,390,000. Vanguard Group Inc. increased its holdings in shares of Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after buying an additional 525,696 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Avalo Therapeutics by 380.2% during the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after buying an additional 522,548 shares during the last quarter. Finally, Seven Fleet Capital Management LP increased its holdings in shares of Avalo Therapeutics by 806.0% during the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock worth $8,568,000 after buying an additional 510,540 shares during the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.